Netherton Syndrome Market

 Market Overview:

The 7 major Netherton syndrome markets reached a value of US$ 21.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 69.7 Million by 2034, exhibiting a growth rate (CAGR) of 11.34% during 2024-2034.

The Netherton syndrome market has been comprehensively analyzed in IMARC's new report titled "Netherton Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Netherton syndrome is a rare hereditary skin disorder caused by mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, expressed in the epidermis and other stratified epithelia. The SPINK5 gene encodes lymphoepithelial Kazal-type inhibitor, which is essential for the epidermal barrier function in the skin. This disease generally affects newborns and is characterized by scaling skin, increased susceptibility to atopic eczema, elevated IgE levels, severe dehydration, stunted growth, etc. Additionally, individuals suffering from Netherton syndrome may experience chronic skin inflammation, itching, mental retardation, failure to thrive, immune system-related problems like hay fever, food allergies, asthma, enteropathy, hemihypertrophy, fragile hair, etc. Diagnosing this ailment typically depends on the presence of characteristic skin symptoms, dermatologic examination, and laboratory tests. The healthcare provider may also perform genetic testing to confirm gene variations and rule out other health conditions. An electron microscopic study of the skin biopsy, in which a small section of the skin is removed for testing, is further required for validating the disease diagnosis in patients.

The rising incidences of rare genetic conditions coupled with the increasing unmet medical demand for novel drugs that can treat the disease effectively are primarily driving the Netherton syndrome market. Besides this, the widespread adoption of effective medications, including topical corticosteroids, keratolytic agents, calcineurin inhibitors, etc., to manage the skin symptoms of the ailment, such as eczema, redness, itching, etc., is further augmenting the market growth. Moreover, the emerging popularity of narrowband ultraviolet B phototherapy to improve cutaneous indications among patients who are not responsive to conventional oral treatments is acting as another significant growth-inducing factor. Additionally, several stakeholders are making extensive investments in R&D activities to launch novel biological therapies with a better understanding of the disease etiopathogenesis. This, in turn, is also creating a positive outlook for the market. Furthermore, the escalating demand for intravenous immunoglobulin on account of its numerous advantages, which include reducing infections, resolving skin and hair abnormalities, promoting treatment outcomes in patients, etc., is expected to drive the Netherton syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Netherton syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Netherton syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Netherton syndrome market in any manner.

Recent Developments:

• In March 2023, Quoin Pharmaceuticals Ltd. received approval from the United States Food and Drug Administration (FDA) to enroll teen participants aged 14 and up in two ongoing clinical trials for QRX003, which is being investigated as a potential treatment for Netherton syndrome. Both studies are taking place under Quoin's open Investigational New Drug Application (IND) for QRX003.

Key Highlights:

• Netherton syndrome affects around one in every 200,000 newborns.
• The disorder's incidence is reported as 1/200,000, with a prevalence of 1-9/1,000,000.
• The prognosis is poor because of the high mortality rates in the early years of life, which range from 10% to 20%.
• The illness has been documented in all ethnicities, with female patients being more afflicted than male ones.
• Around 75% of Netherton syndrome patients have an atopic diathesis and will be affected by food allergies, atopic dermatitis, asthma, peripheral eosinophilia, hay fever, and increased immunoglobulin E (IgE) levels.

Drugs:

QRX003 is a topical lotion made using patented delivery technology that incorporates a broad-spectrum serine protease inhibitor. Its mode of action is intended to perform the role of a specific protein known as LEKTI. The absence of LEKTI in Netherton patients causes extensive skin shedding, resulting in a porous and weakened skin barrier. QRX003 is intended to promote regulated skin shedding and the creation of a stronger, more effective skin barrier.

SXR1096 is a novel, powerful, and selective small molecule inhibitor of kallikreins 5, 7, and 14. The chemical is packaged as a customized skin lotion that is intended for everyday usage in patients with Netherton syndrome.

DS-2325a is being developed by Daiichi Sankyo for the treatment of Netherton Syndrome. The treatment candidate uses an adeno-associated virus (AAV) to deliver the gene. It is administered via intravenous and subcutaneous routes. It works by specifically targeting kallikrein 5.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Netherton syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Netherton syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Netherton syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Netherton syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Netherton syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Netherton syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Netherton syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Netherton syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Netherton syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Netherton syndrome across the seven major markets?
• What is the size of the Netherton syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Netherton syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Netherton Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Netherton syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Netherton syndrome market?
• What are the key regulatory events related to the Netherton syndrome market?
• What is the structure of clinical trial landscape by status related to the Netherton syndrome market?
• What is the structure of clinical trial landscape by phase related to the Netherton syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Netherton syndrome market?